NCT03276832 - Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

October 1, 2021

Study Completion Date

December 31, 2025

Conditions

Metastatic MelanomaStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

DRUG

Imiquimod

Applied cutaneously

PROCEDURE

Biopsy

Undergo biopsy

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

Trial Locations (1)

Mayo Clinic in Florida, Jacksonville